Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

284 13 Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy
98 Kadowaki, N., Antonenko, S. and
Liu,Y. J. Distinct CpG DNA and polyinosinic±polycytidylic
acid doublestranded
RNA, respectively, stimulate
CD11c(±) type 2 dendritic cell precursors
and CD11c(+) dendritic cells to
produce type I IFN. J Immunol 2001;
166: 2291±2295.
99 Sester, D. P., Naik, S., Beasley, S. J.,
Hume, D. A. and Stacey, K. J. Phosphorothioate
backbone modification
modulates macrophage activation by
CpG DNA. J Immunol 2000; 165: 4165±
4173.
100 Vallin, H., Perers, A., Alm, G. V. and
Ronnblom, L. Anti-double-stranded
DNA antibodies and immunostimulatory
plasmid DNA in combination mimic
the endogenous IFN-a inducer in
systemic lupus erythematosus. J Immunol
1999; 163: 6306±6313.
101 Krieg, A. M. Now I know my CpGs.
Trends Microbiol 2001; 9: 249±252.
102 Krug, A., Rothenfusser, S., Hornung,V.,
et al. Identification of CpG oligonucleotide
sequences with high induction
of IFN-ab in plasmacytoid dendritic
cells. Eur J Immunol 2001; 31:
2154±2163.
103 Neujahr, D. C., Reich, C. F. and
Pisetsky, D. S. Immunostimulatory
properties of genomic DNA from different
bacterial species. Immunobiology
1999; 200: 106±119.
104 Kimura,Y., Sonehara, K., Kuramoto,
E., et al. Binding of oligoguanylate
to scavenger receptors is required
for oligonucleotides to augment NK cell
activity and induce IFN. J Biochem
(Tokyo) 1994; 116: 991±994.
105 Lipford, G. B., Sparwasser, T.,
Bauer, M., et al. Immunostimulatory
DNA: sequence-dependent production
of potentially harmful or useful cytokines.
Eur J Immunol 1997; 27: 3420±
3426.
106 Shankaran,V., Ikeda, H., Bruce, A. T.,
et al. IFNg and lymphocytes prevent primary
tumour development and shape
tumour immunogenicity. Nature 2001;
410: 1107±1111.
107 Dow, S. W., Fradkin, L. G., Liggitt,
D. H., et al. Lipid±DNA complexes
induce potent activation of innate im-
mune responses and antitumor activity
when administered intravenously. JImmunol
1999; 163: 1552±1561.
108 Lanuti, M., Rudginsky, S., Force, S. D.,
et al. Cationic lipid:bacterial DNA complexes
elicit adaptive cellular immunity
in murine intraperitoneal tumor models.
Cancer Res 2000; 60: 2955±2963.
109 Ballas, Z. K., Krieg, A. M.,Warren, T.,
et al. Divergent therapeutic and immunologic
effects of oligodeoxynucleotides
with distinct CpG motifs. J Immunol
2001; 167: 4878±4886.
110 Carpentier, A. F., Chen, L., Maltonti,
F. and Delattre, J. Y. Oligodeoxynucleotides
containing CpG motifs
can induce rejection of a neuroblastoma
in mice. Cancer Res 1999; 59:
5429±5432.
111 Carpentier, A. F., Xie, J., Mokhtari,
K. and Delattre, J. Y. Successful
treatment of intracranial gliomas in rat
by oligodeoxynucleotides containing
CpG motifs. Clin Cancer Res 2000; 6:
2469±2473.
112 Blazar, B. R., Krieg, A. M. and
Taylor, P. A. Synthetic unmethylated
cytosine±phosphate±guanosine oligodeoxynucleotides
are potent stimulators
of antileukemia responses in naive and
bone marrow transplant recipients.
Blood 2001; 98: 1217±1225.
113 Hartmann, G. and Krieg, A. M.
Mechanism and function of a newly
identified CpG DNA motif in human
primary B cells. J Immunol 2000; 164:
944±953.
114 Davis, H. L., Suparto, I. I., Weeratna,
R. R., et al. CpG DNA overcomes
hyporesponsiveness to hepatitis B vaccine
in orangutans [In process citation].
Vaccine 2000; 18: 1920±1924.
115 Jones, T. R., Obaldia, N., III, Gramzinski,
R. A., et al. Synthetic oligodeoxynucleotides
containing CpG motifs enhance
immunogenicity of a peptide malaria
vaccine in Aotus monkeys. Vaccine
1999; 17: 3065±3071.
116 Krieg, A. M. and Davis, H. L. Enhancing
vaccines with immune stimulatory
CpG DNA. Curr Opin Mol Ther 2001; 3:
15±24.
117 Sparwasser,T.,Vabulas, R. M.,Villmow,
B., Lipford, G. B. and Wagner, H.